Partners

GEROPHARM is an international producer of biotechnology products specializing in neurology, endocrinology, ophthalmology, gynecology, and urology. Its’ portfolio includes 35 original medicines and generics. GEROPHARM tops the Russian insulin market and is among the top 10 insulin manufacturers in the world. The Company runs all production stages at its own facilities in Russia by GxP standards. In 2023 GEROPHARM registered Semavic®, Russia's first Ozempic® analog, and in 2025 presented Mounjaro analog – Sejaro®. Medicinal products of the Company are represented in 14 countries.

The modern, dynamically developing Russian pharmaceutical company, one of the leaders in the pharmaceutical industry of the Russian Federation in terms of growth rates.

Skopinpharm is a developer and manufacturer of medicines, one of the leading suppliers under the program of 14 high-cost nosologies in accordance with the Ministry of Health of the Russian Federation orders. Skopinpharm offers a range of medications under the regional preferential insurance program, and is also one of the main suppliers of the Circle of Good Foundation for helping children with serious and life-threatening illnesses. The company's turnover amounted to more than 44.1 billion rubles by 2024.

The company operates in the following key areas: manufacture of plasma-derived medicinal products, cytostatics, and medicinal products used for the treatment of various oncological diseases. the company has constructed new manufacturing and storage buildings, performs technology transfer of unique pharmaceutical manufacturing processes, and has built a plasma storage facility with a laboratory unit.

At the same time, in partnership with health authorities, a modern system for the procurement of blood plasma is being created and a voluntary donation program is being developed.

Skopinpharm actively supports the training and advanced training of pharmaceutical industry specialists and is one of the founders of the Academy of Good Practices of the EAEU

The Association of Medical Specialists for Risk Modification was established in 2021 to attract the attention of the medical community and the general public to solving the problems of managing modifiable risk factors in order to prevent, effective primary and secondary prevention, treatment and rehabilitation of chronic non-communicable diseases, other syndromes, conditions and injuries leading to a loss of autonomy, a decrease in the quality and life expectancy of citizens. The focus of the Association's activities is the development and implementation at the federal level of programs for the comprehensive improvement of the quality of life of patients through the modification of risk factors and the creation of long-term motivation to change consumer behavior. The Association strive to organize a dialogue between all participants in the risk modification process - regulators, doctors, patients, social workers, business representatives.

PJSC Sberbank is Russia’s largest bank and a leading global financial institution. Holding almost one-third of aggregate Russian banking sector assets, Sberbank is the key lender to the national economy and one of the biggest deposit takers in Russia. The Government of the Russian Federation represented by the Ministry of Finance of the Russian Federation is the principal shareholder of PJSC Sberbank owning 50% plus one voting share of the bank’s authorized capital, with the remaining 50% minus one voting share held by domestic and international investors. It holds general banking license No. 1481 dd. August 11, 2015, from the Bank of Russia.

Swixx Group is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit.

Swixx Group of companies and affiliates operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America.

With more than 1,600 employees and sales which exceeded 1.1 billion Euros in 2024, the company is one of the fastest-growing independent commercialization platforms for biopharma globally.

Swixx has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof.

For more information about Swixx, please visit: www.swixxbiopharma.com.

Sun Pharma is an international pharmaceutical company headquartered in India, ranking among the top global pharma corporations. Since its foundation in 1983, Sun Pharma has been providing high-quality medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe.

Sun Pharma has been operating in Russia since 1993 and is ranked among the top 30 leading pharmaceutical companies. The Russian division’s operations encompass production, distribution, and marketing of medicines in key therapeutic areas such as women's and men's health, common cold treatments, dermatology, central nervous system disorders, ophthalmology, etc.

In 2024, Sun Pharma introduced its first innovative medication for basal cell carcinoma skin cancer “Odomzo” (sonidegib) onto the Russian market. The company continues developing innovative drugs focusing on strategic areas like dermatology, oncological dermatology, rheumatology, and ophthalmology.

Production of medical X-ray equipment.

SIBUR is one of the fastest growing companies in the global petrochemical industry.

We produce in-demand products for society and use advanced technologies to create new opportunities, invest in social infrastructure and improve the quality of people’s lives. We evolve through partnership and sharing of experience, continuous growth, pursuit of ambitious goals and commitment to sustainability.

SIBUR's polymer solutions are successfully used in the production of medical devices, pharmaceuticals and pharmaceutical packaging, hygiene products.